Tag: PRO MEDICUS

Glennon Small Companies Ltd has outperformed its benchmark in January 2025 with a 4.66% return, largely due to successful investments in Telix Pharmaceuticals and Pro Medicus. Despite challenges from Zip Co, the portfolio’s 12-month return is 27.35%, notably higher than the benchmark’s 12.32%. The firm, focused on small-cap investments, has a year-to-date performance of -2.08%…